Even in the absence of genetic alterations, merlin levels have been shown to be down regulated, or its activation inhibited, in mesothelioma [29], glioma [25], prostate [30], and breast cancer [31]; and merlin has been shown to play significant roles in inhibiting the progression of these cancer types [25], [29], [30], [31]. The gene discussed is NF2; the disease is central nervous system cancer.